Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial

 

New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significantly impact disease disability. In the RADIANCE trial, 1,313 patients with relapsing MS were randomized to receive either 0.5 mg or 1 mg of ozanimod, a sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, or weekly interferon beta-1a (Avonex), over a two-year period. Both doses of ozanimod demonstrated significant and clinically meaningful reductions in the annualized relapse rate versus Avonex, while the oral selective S1P 1 and 5 receptor modulator also achieved significance for the two key secondary endpoints.

However, ozanimod was not associated with a significant difference in the rate of disease progression versus Avonex, based on a pre-specified pooled analysis of data from the RADIANCE trial and the late-stage SUNBEAM study reported earlier this year.

Celgene is expected to submit a New Drug Application to the FDA later this year.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC